Rose, My guess is that nobody knows when China will give official
approval. The reason why Edding was selected a very long time ago
was because of BOD connections and not who would be the best company
to get approval for Vascepa in China. (Again, it goes to past management
incompetence.) Edding has a lot on the line here and they paid AMRN
for the rights to Vascepa so this delay must be very disheartening for
them. Regardless, I understand that once approval is granted there
is a 5 year exclusivity period granted. What might be the protections
beyond that? I do not know. I do believe that Pfizer has clout in
China, and if they end up getting involved either through a JV with
Edding or a BO of AMRN, Pfizer would be in a position to make Vascepa
a winner in China, at least beyond what Edding and AMRN could achieve
by themselves. In other words if Pfizer became involved they could
help insure that the uptake of Vascepa in China is optimized...Regardless
of when that begins.
News 
Market Data 
Discover 
AI
